Clinuvel Pharmaceuticals Ltd (CLVLF) stock
Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –
Clinuvel Pharmaceuticals Ltd grew revenue 5.2% to $64.32M over fiscal 2026. Operating income rose 5.3% to $27.92M, moving the operating margin from 43.4% to 43.4%. Free cash flow was $11.85M, down 56.3% from a year earlier. At the latest close the market valued the company at $254.66M, 11.0 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $254.66M
- P/E ratio
- 11.0
- Price to sales
- 3.96
- Price to book
- 1.35
- Dividend yield
- –
- Free cash flow yield
- 4.65%
Fundamentals
- Revenue
- $64.32M
- Net income
- $23.18M
- EPS, diluted
- $0.46
- Free cash flow
- $11.85M
Trading
- Previous close
- $5.38
- Open
- $5.46
- Day's range
- $5.05 – $5.46
- Volume
- 17,844
- Beta (5 years)
- 0.81
- 52-week range
- $4.81 – $8.92
- RSI (14 days)
- 44.0
- Volatility (1 year)
- 48.9%
- Relative volume
- 0.39×
- WACC
- 8.9%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLVLF | S&P 500 | Difference | CLVLF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.3% | +0.6% | −14.9 pts | ||
| 3 months | -17.2% | +3.4% | −20.6 pts | ||
| Year to date | -34.4% | +13.3% | −47.7 pts | ||
| 1 year | -32.0% | +16.6% | −48.6 pts | ||
| 3 years | -51.2% | +86.4% | −137.6 pts | -21.3% | +23.1% |
| 5 years | -83.1% | +81.9% | −164.9 pts | -29.9% | +12.7% |
| 10 years | -2.9% | +318.9% | −321.8 pts | -0.3% | +15.4% |
Four years at a glance
Fiscal years 2023 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Clinuvel Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Clinuvel Pharmaceuticals
American Depositary Receipts
CLINUVEL PHARMACEUTICALS LIMITED is a biopharmaceutical company focused on the development and commercialization of treatments for severe genetic, skin, and metabolic disorders. The company's primary commercial product is SCENESSE, a systemic photoprotective drug designed for the prevention of phototoxicity in adult patients suffering from erythropoietic protoporphyria. In addition to commercializing SCENESSE, the company undertakes clinical development programs, including evaluations of therapeutic candidates for conditions such as vitiligo. Its customer base includes accredited medical centers and hospitals that administer specialized treatments, along with patients receiving therapies through commercial sales and special access reimbursement programs.
Company profile, executives and historyClinuvel Pharmaceuticals stock: common questions
What is Clinuvel Pharmaceuticals's stock price?
CLVLF closed at $5.05 on Oct 19, 2026, down 6.13% on the day. Over the past 52 weeks it traded between $4.81 and $8.92.
What is Clinuvel Pharmaceuticals's market cap?
Clinuvel Pharmaceuticals was worth $254.66M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CLVLF's P/E ratio?
CLVLF trades at 11.0 times earnings, based on diluted earnings per share of $0.46 over fiscal 2026.
How much revenue does Clinuvel Pharmaceuticals make?
Clinuvel Pharmaceuticals reported revenue of $64.32M for fiscal 2026, up 5.2% from a year earlier.
Does Clinuvel Pharmaceuticals pay a dividend?
No. Clinuvel Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has CLVLF stock performed over the past year?
Including dividends, CLVLF returned -32.0% over the past year, against +16.6% for the S&P 500.
Who are Clinuvel Pharmaceuticals's competitors?
Companies most similar to Clinuvel Pharmaceuticals by business, industry and size include VRDN, BFRI, PLX, FBIO, ETON.
See a number that looks wrong?